A Delaware federal judge has dismissed an infringement lawsuit from Bristol-Myers Squibb and Pfizer seeking to block a generic version of their patented blood thinner drug Eliquis, finding that venue in the First State was improper after the U.S. Supreme Court’s landmark decision in TC Heartland.

The 12-page ruling, from U.S. District Chief Judge Leonard P. Stark of the District of Delaware, followed more than eight months of venue discovery, and rejected an attempt by Bristol-Myers Squibb to attribute the Delaware residency of a Mylan Pharmaceuticals subsidiary to the parent company, which is incorporated in West Virginia.